immunotherapy world

Immunotherapy World 2017 Agenda

Loading
  1. Registration & breakfast in the exhibition area
  1. Recent Advances in Immuno-Oncology and where it takes clinical care and the industry in the near future

  2. Recent Advances in Immuno-Oncology and where it takes clinical care and the industry in the near future

  3. Recent Advances in Immuno-Oncology and where it takes clinical care and the industry in the near future

  4. Recent Advances in Immuno-Oncology and where it takes clinical care and the industry in the near future

  5. Recent Advances in Immuno-Oncology and where it takes clinical care and the industry in the near future

  1. Morning coffee in the exhibition hall
  1. Adoptive T cell immunotherapy business model: Who has the lead in removing barriers to commercial success?

  2. Adoptive T cell immunotherapy business model: Who has the lead in removing barriers to commercial success?

  3. Adoptive T cell immunotherapy business model: Who has the lead in removing barriers to commercial success?

  4. Adoptive T cell immunotherapy business model: Who has the lead in removing barriers to commercial success?

  1. Buffet lunch in the exhibition area
  1. Assessing efficacy and response in cancer immunotherapy trials

  2. Assessing efficacy and response in cancer immunotherapy trials

  3. Assessing efficacy and response in cancer immunotherapy trials

  4. Assessing efficacy and response in cancer immunotherapy trials

  5. Assessing efficacy and response in cancer immunotherapy trials

  6. Assessing efficacy and response in cancer immunotherapy trials

  1. Afternoon tea in the exhibition area
  1. Close of day 1, followed by a drinks reception in the exhibition area
  1. Registration & breakfast in the exhibition area
  1. Future Outlooks: Combination Cancer Therapies with Immune Checkpoint Blockade

  2. Future Outlooks: Combination Cancer Therapies with Immune Checkpoint Blockade

  3. Future Outlooks: Combination Cancer Therapies with Immune Checkpoint Blockade

  4. Future Outlooks: Combination Cancer Therapies with Immune Checkpoint Blockade

  5. Future Outlooks: Combination Cancer Therapies with Immune Checkpoint Blockade

  1. Which combination therapy strategies will help realize the full potential of CAR T cell and TCR-based immunotherapies?

  2. Which combination therapy strategies will help realize the full potential of CAR T cell and TCR-based immunotherapies?

  3. Which combination therapy strategies will help realize the full potential of CAR T cell and TCR-based immunotherapies?

  4. Which combination therapy strategies will help realize the full potential of CAR T cell and TCR-based immunotherapies?

  5. Which combination therapy strategies will help realize the full potential of CAR T cell and TCR-based immunotherapies?

  1. Immuno-oncology combinations to unleash the full power of cancer vaccines, oncolytic virus therapies and the innate immune system

  2. Immuno-oncology combinations to unleash the full power of cancer vaccines, oncolytic virus therapies and the innate immune system

  3. Immuno-oncology combinations to unleash the full power of cancer vaccines, oncolytic virus therapies and the innate immune system

  1. Defining the critical hurdles in translational science for Immuno-Oncology therapies

  2. Defining the critical hurdles in translational science for Immuno-Oncology therapies

  3. Defining the critical hurdles in translational science for Immuno-Oncology therapies

  4. Defining the critical hurdles in translational science for Immuno-Oncology therapies

  5. Defining the critical hurdles in translational science for Immuno-Oncology therapies

  1. Taking up Immuno-Oncology challenges: Bispecific molecules, the path forward?

  2. Taking up Immuno-Oncology challenges: Bispecific molecules, the path forward?

  3. Taking up Immuno-Oncology challenges: Bispecific molecules, the path forward?

  4. Taking up Immuno-Oncology challenges: Bispecific molecules, the path forward?

  5. Taking up Immuno-Oncology challenges: Bispecific molecules, the path forward?

  1. Afternoon tea in the exhibition area
  1. Capitalizing on the convergence of immunotherapy and existing standards of care

  2. Capitalizing on the convergence of immunotherapy and existing standards of care

  3. Capitalizing on the convergence of immunotherapy and existing standards of care

  4. Capitalizing on the convergence of immunotherapy and existing standards of care

  5. Capitalizing on the convergence of immunotherapy and existing standards of care

  1. New therapeutic approaches - Expanding the reach of cancer immunotherapy to all patients in need of better treatment

  2. New therapeutic approaches - Expanding the reach of cancer immunotherapy to all patients in need of better treatment

  3. New therapeutic approaches - Expanding the reach of cancer immunotherapy to all patients in need of better treatment

  1. Close of day 2 - Boat Party!
  1. Registration & breakfast in the exhibition area
  1. Morning coffee in the exhibition area
  1. Break for Inauguration speech
  1. Close of Phacilitate’s Immunotherapy World Forum

It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer.

Lance Leopold MD, Vice President, Head of Oncology Development, Incyte Corporation